NASDAQ$CLDX
Celldex Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Celldex reported Q4 2025 revenue of $0.1 million with a net loss of $81.3 million ($1.22 per share) as barzolvolimab Phase 3 enrollment completed early.
Celldex reported Q4 2025 total revenue of $0.1 million and a net loss of $81.3 million ($1.22 per share) as R&D expenses rose to $75.3 million on accelerated barzolvolimab Phase 3 CSU trials. Cash was $518.6 million at year-end. Enrollment in EMBARQ-CSU1 and EMBARQ-CSU2 finished six months ahead of schedule (1,939 patients); topline data are expected Q4 2026 with a planned 2027 BLA. The company believes cash is sufficient through 2027.
- Phase 3 CSU enrollment completed six months early across 43 countries.
- Q4 net loss $81.3M on R&D $75.3M; cash $518.6M.
- Topline CSU data expected Q4 2026; BLA targeted 2027.
- Phase 3 cold urticaria/dermographism study initiated.
Headline financials
Revenue & EPS history
Celldex · Revenue · Quarterly
$121K
Forward guidance
Celldex guided that year-end 2025 cash is sufficient for planned operations through 2027; no product revenue guidance until barzolvolimab potential approval.
Tailwinds
- Largest CSU Phase 3 program completed enrollment ahead of schedule.
- Strong cash runway for pivotal readouts and filing.
- Expanding barzolvolimab indications in urticaria portfolio.
Headwinds
- No commercial revenue; rising burn from clinical and manufacturing prep.
- Binary clinical/regulatory outcomes on 2026–2027 timelines.
- Competitive landscape in CSU and mast-cell pathways.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2025
+1.3%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+1.7%
Avg return
30 days after
59%
38 / 64 earnings
Positive
+35.2%
Q4 2023
Best reaction
-21.5%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.2% | -7.0% | -16.8% | |
| Q4 2025 | -0.6% | -6.1% | -1.7% | |
| Q3 2025 | +7.6% | +12.7% | +23.2% | |
| Q1 2025 | +2.2% | -0.4% | -0.5% | |
| Q4 2024 | -1.6% | -3.1% | -3.4% | |
| Q3 2024 | +4.1% | +3.1% | +5.3% | |
| Q2 2024 | +2.7% | +3.8% | +36.5% | |
| Q1 2024 | -0.8% | -6.2% | -22.4% | |
| Q4 2023 | +35.2% | +37.4% | +10.7% | |
| Q3 2023 | +10.2% | +23.1% | +35.9% | |
| Q2 2023 | -6.5% | -7.4% | -13.3% | |
| Q1 2023 | +5.8% | +5.3% | +5.5% | |
| Q4 2022 | +7.9% | +8.7% | -17.4% | |
| Q3 2022 | +9.4% | +5.6% | +7.5% | |
| Q2 2022 | -3.8% | +1.7% | -17.7% | |
| Q1 2022 | -10.3% | -10.6% | -23.4% | |
| Q4 2021 | +4.7% | +0.5% | +14.7% | |
| Q3 2021 | +0.6% | -7.6% | -18.1% | |
| Q2 2021 | +6.2% | +3.7% | +20.9% | |
| Q1 2021 | -1.3% | -3.3% | +0.8% | |
| Q4 2020 | -16.9% | -4.0% | +30.4% | |
| Q3 2020 | +1.4% | +9.6% | +10.3% | |
| Q2 2020 | -3.5% | -12.3% | -7.5% | |
| Q1 2020 | +0.4% | +0.4% | +29.4% | |
| Q4 2019 | +3.4% | -7.3% | +68.2% | |
| Q3 2019 | -2.5% | -5.0% | -7.9% | |
| Q2 2019 | +6.2% | +1.4% | +2.9% | |
| Q1 2019 | -6.6% | -15.4% | -36.1% | |
| Q4 2018 | +9.0% | +4.3% | -7.3% | |
| Q3 2018 | +15.2% | +3.0% | -21.2% | |
| Q2 2018 | +0.0% | -6.7% | +2.2% | |
| Q1 2018 | -5.2% | -7.8% | -15.6% | |
| Q4 2017 | +14.1% | +17.0% | -17.4% | |
| Q3 2017 | +15.5% | +14.7% | +23.1% | |
| Q2 2017 | +2.4% | -0.8% | +11.7% | |
| Q1 2017 | +0.7% | +2.9% | -23.5% | |
| Q4 2016 | +1.8% | +2.1% | -2.1% | |
| Q3 2016 | +22.3% | +39.8% | +21.7% | |
| Q2 2016 | +0.4% | -4.3% | -21.5% | |
| Q1 2016 | -8.9% | — | — | |
| Q4 2015 | +10.9% | — | — | |
| Q3 2015 | +5.4% | — | — | |
| Q2 2015 | -21.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +0.9% | — | — | |
| Q3 2014 | -21.5% | — | — | |
| Q2 2014 | +4.0% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | -5.2% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +13.3% | — | — | |
| Q3 2012 | +5.9% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | +2.6% | — | — | |
| Q3 2011 | -3.6% | — | — | |
| Q2 2011 | -15.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | +7.6% | — | — | |
| Q2 2010 | -3.9% | — | — | |
| Q1 2010 | -2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro